BeOne Medicines Ltd. (ONC), initially founded in 2010 as BeiGene, stands as a prominent global oncology enterprise committed to identifying, advancing, and bringing to market cutting-edge cancer treatments. The company underwent a significant transformation, rebranding as BeOne in late 2024 and subsequently relocating its headquarters from Cambridge, Massachusetts, to Basel, Switzerland, in 2025. With a vast operational footprint extending across more than 45 countries and six continents, BeOne has firmly established itself as a leader in both immuno-oncology and targeted therapy solutions. Its strong product lineup includes key assets such as Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved worldwide for a variety of cancer types, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that has surpassed $1.3 billion in annual revenue and is approved in major regions like the U.S., Europe, and China. BeOne's strategic foundation combines proprietary research and development efforts with the integration of compounds obtained through external alliances, thereby fueling a comprehensive pipeline addressing both blood cancers and solid tumors.
